Departments of Research and Medicine, Veterans Affairs Medical Center, Northport, New York and State University of New York Stony Brook, New York, USA
s_zucker@yahoo.com
Better clinical endpoints are needed to monitor the efficacy of drugs designed to block enzymatic function, such as matrix metalloproteinase inhibitors. A new imaging technique allows researchers to monitor native enzymatic activity in vivo, and more effectively evaluate the therapeutic potential of these drugs (pages 743−748).
